AI-generated summary
This review examines newer treatment options for immune-mediated diseases with oral signs, including topical calcineurin inhibitors, biologic agents, natural products, photodynamic therapy and low-level laser therapy. The authors report that topical calcineurin inhibitors have been used successfully for oral lichen planus and pemphigus vulgaris, and that low-level laser therapy has shown positive results, while the use of photodynamic therapy is described as contentious. The authors describe these approaches as possible adjuncts to standard care.
- Who or what was studied
- Patients with immune-mediated diseases that have oral presentations, such as oral lichen planus and pemphigus vulgaris
- Limits stated in the abstract
- The abstract does not report included studies, sample sizes or the strength of the evidence for each treatment.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on linkinghub.elsevier.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Low-level laser therapy, Photodynamic therapy, Light-emitting diode, Inflammation, Wavelength, Laser. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.